Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2019
SIETES contiene 92806 citas

 
 
 1 a 20 de 6942 siguiente >>
Presentar resultados
Seleccionar todas
2. Cita con resumen
Khan R, Nugent CM, Scaffidi MA, Gimpaya N, Grover SC. Association of biologic prescribing for inflammatory bowel disease with industry payments to physicians. JAMA Intern Med 2019;179:8 de julio. [Ref.ID 103170]
3. Cita con resumen
5. Cita con resumen
Beddoes ZM. Johnson & Johnson, Purdue and other opioid-peddlers face a reckoning. The Economist 2019:1. [Ref.ID 103165]
6.Enlace a cita original Cita con resumen
Egilman AC, Zhang AD, Wallach JD, Ross JS. Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors . Ann Intern Med 2019:1. [Ref.ID 103162]
7. Cita con resumen
Randolph AC, Lin Y-L, Volpi E, Kuo Y-F. Tricyclic antidepressant and/or ?-aminobutyric acid–analog use is associated with fall risk in diabetic peripheral neuropathy. J Am Geriatr Soc 2019;67:junio. [Ref.ID 103149]
8.Enlace a cita originalTiene citas relacionadas Cita con resumen
Taylor P. Ex-FDA chief Gottlieb's quick move to pharma raises eyebrows. PMLiVE 2019:28 de junio. [Ref.ID 103148]
10.Enlace a cita original Cita con resumen
Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie MA, Cutter GR, Kaye WE, Wagner L, Tremlett H, Buka SL, Dilokthornsakul P, Topol B, Chen LH, LaRocca NG, US Multiple Sclerosis Prevalence Workgroup. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology 2019;92:5 de marzo. [Ref.ID 103132]
11. Cita con resumen
Healy D. EMA acknowledges persistent sexual dysfunction after SSRIs & SNRIs. Rxisk 20019:11 de junio. [Ref.ID 103130]
12.Enlace a cita original Cita con resumen
Kim J, Farchione T, Potter A, Chen Q, Temple R. Esketamine for treatment-resistant depression — First FDA-approved antidepressant in a new class. N Engl J Med 2019;381:4 de julio. [Ref.ID 103124]
13.Enlace a cita original Cita con resumen
Tatsioni A, Karassa FB, Goodman SN, Zarin DA, Fanelli D, Ioannidis JPA. Lost evidence from registered large long-unpublished randomized controlled trials: a survey. Ann Intern Med 2019:7 de mayo. [Ref.ID 103117]
15.Enlace a cita original Cita con resumen
Garmendia CA, Gorra LN, Rodríguez AL, Trepka MJ, Veledar E, Madhivanan P. Evaluation of the inclusion of studies identified by the FDA as having falsified data in the results of meta-analyses. The example of the apixaban trials. JAMA Intern Med 2019;179:4 de marzo. [Ref.ID 103094]
16.Enlace a cita original Cita con resumen
Podolsky SH, Herzberg D, Greene JA. Preying on prescribers (and their patients) — Pharmaceutical marketing, iatrogenic epidemics, and the Sackler legacy. N Engl J Med 2019:10 de abril. [Ref.ID 103090]
18.Enlace a cita original Cita con resumen
Anónimo. FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture. U.S. Food and Drug Administration 2019:9 de abril. [Ref.ID 103084]
19. Cita con resumen
Seleccionar todas
 
 1 a 20 de 6942 siguiente >>